Wegovy vs. Ozempic: What’s the Real Difference? Chattanooga Guide
I’m an emergency and Family Medicine physician in Chattanooga, Tennessee, and founder of Summit Metabolic Health. I read every patient chart personally. This article reports on a topic patients keep asking about — it is education, not an endorsement.
I get this question from patients across Chattanooga almost every week, usually typed into a search bar before it ever comes up in a visit: what’s actually different between Wegovy and Ozempic? The honest answer is the one the TV ads skip. They’re the same drug. The real decision isn’t the brand name on the pen — it’s the dose, whether insurance will pay for it, and whether you can actually get it. I’m Dr. Paul Miranda, board-certified, and I’ll walk through what the difference really is, then where it leaves patients trying to get treated.
Wegovy and Ozempic are both semaglutide, made by the same manufacturer, Novo Nordisk. Same molecule, same mechanism, same pen technology. The difference is the dose and the FDA-approved indication printed on the label. Ozempic is approved for type 2 diabetes, dosed up to a 2.0mg maintenance ceiling. Wegovy is approved for chronic weight management, dosed up to 2.4mg. That 0.4mg gap is the entire “difference” — not a different drug, a different ceiling on the same drug, approved for a different reason.
Why two brand names for one molecule? Regulatory and marketing strategy, not pharmacology. Novo Nordisk ran separate FDA approval tracks for separate indications, then gave each one its own name, its own packaging, and its own ad campaign. A patient searching “Wegovy vs. Ozempic” is really asking “why does this cost different and get covered different if it’s the same thing” — and that’s a fair question, because it is the same thing.
The dose difference isn’t cosmetic. It’s the entire clinical story. In the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), adults with obesity who weren’t diabetic took semaglutide 2.4mg — the Wegovy dose — and lost a mean of 14.9% of body weight at 68 weeks, against 2.4% on placebo. That’s the data behind the weight-loss indication, run at the higher dose, in a non-diabetic population.
Ozempic’s diabetes trials top out at 2.0mg because that’s the dose that controls blood sugar without pushing tolerability further than a diabetes population needs. The mechanism is identical across both: semaglutide slows gastric emptying, drives glucose-dependent insulin secretion, and signals satiety centrally in the brain (Drucker, Cell Metabolism, 2018). Same biology, same molecule — the dose is tuned to the job it’s approved to do. That’s why you cannot simply ask your doctor to “prescribe Ozempic for weight loss” and expect the same trial-proven result as Wegovy — the ceiling is lower by design, for a different approved use.
Trial averages are group data, not a promise about any one patient. What they tell you is that the dose, not the label on the box, is what moved the number.
Here’s where the brand name actually starts to matter, even though the drug doesn’t change. Insurers build formularies around the FDA-approved indication on the label, not the molecule inside the pen. A plan covering Ozempic for a diabetes diagnosis will often deny Wegovy for a weight-loss diagnosis outright, or require a prior authorization and a documented failure of other treatments first. I’ve laid out exactly how that plays out for Tennessee plans in a breakdown of GLP-1 insurance coverage in Tennessee — the short version is that coverage follows the diagnosis code, and a lot of Chattanooga patients get denied for the exact reason that has nothing to do with whether the drug will work for them.
That leaves a gap: a patient who needs the 2.4mg weight-loss dose, whose plan won’t pay for Wegovy, and whose only other listed option is an off-label Ozempic prescription capped at a lower dose than the one the trial data actually used.
I see this exact scenario in Chattanooga regularly: a patient with prediabetes or early insulin resistance gets approved for Ozempic because the diagnosis code reads “diabetes risk,” then hits a 2.0mg ceiling that was never tested for weight loss at the rate the STEP 1 data showed. Nobody explains that the ceiling, not the drug, is why the number on the scale stalls. That’s a coverage design problem, not a treatment failure, and it’s worth knowing which one you’re actually dealing with before you assume the medication stopped working.
Without insurance, both Wegovy and Ozempic sit at Novo Nordisk’s list price, and that price has moved in one direction for years. That’s a real cliff for a patient paying cash, and it’s the reason compounded semaglutide exists as a legitimate category, not a shortcut. A licensed compounding pharmacy prepares the same active pharmaceutical ingredient — semaglutide — to an individual prescription, billed by the dose a patient is actually on rather than a fixed pen price set for the highest strength in the lineup. I’ve written the full cost comparison, numbers included, in compounded semaglutide vs. Ozempic: what it costs in Chattanooga.
The gap that actually matters to a patient isn’t Wegovy-vs-Ozempic. It’s branded list price vs. a flat, disclosed compounded rate at the dose you’re actually using — and whether the place dispensing it discloses that rate before you call, or makes you ask.
Compounded isn’t a workaround for patients who can’t afford brand-name pricing — it’s a different, equally legitimate way of sourcing the same active ingredient, prepared under a pharmacy license instead of a manufacturer’s fixed-dose pen. The risk in that category has never been the compounding itself. It’s sourcing: where the ingredient came from, whether the pharmacy is licensed, and whether a physician is actually reviewing the dose before it ships. Price alone doesn’t tell you which of those boxes a provider has checked — a disclosed, flat rate tied to physician review is what separates a legitimate compounded option from a shortcut.
A national telehealth site will answer “what’s the difference between Wegovy and Ozempic” accurately and still leave out the part that decides your outcome: who is actually reviewing your chart before your dose changes. An algorithm that advances your dose on a fixed calendar doesn’t know your GI tolerance, your labs, or your history. I personally review every chart at Summit — not a questionnaire run through software, not a nurse queue — and I built the practice around a slower, individualized titration instead of the fastest schedule the label allows.
That difference compounds over months, especially around dose changes and side effects, which is the exact gap I cover in what to actually look for in a GLP-1 provider in Chattanooga. The brand name on the box was never the variable that determined whether your treatment went well.
If you’ve been stuck choosing between a Wegovy denial and an off-label Ozempic workaround, the better question is which dose and delivery actually fits your situation — not which brand name you ask for. That’s a conversation with a physician who reads your chart, not a brand-name decision made at checkout. You can find more on the full Summit approach on our blog, where I cover the clinical and cost side of every GLP-1 question we get asked in this city.
Ready to start? Apply at summitmetabolichealth.com/apply.
This post is for educational purposes and is not a substitute for individualized medical advice. Treatment decisions, including dose and medication choice, are made between you and your physician based on your full history.
